Leerink Downgrades Kythera, Says Allergan Deal Likely To Close At $75 Mark

By: via Benzinga
In a report published Monday, Leerink analyst Seamus Fernandez downgraded the rating on Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.